Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
gut-selective dose of sitagliptin using 1-way ANOVA with Tukeys correction for multiple comparisons for indicated groups
Baz M, Boivin G
Well, folks are still duking it out over this one
Eosinophil depletion induces a shift towards inflammatory macrophages Considering a possible immunoregulatory role of eosinophils, we next addressed the impact of eosinophil deficiency on various immune cell compartments using scRNA-seq
US$ 26.21
US$ 22.68
US$ 21.77
US$ 25.78
US$ 22.05
US$ 23.57
US$ 29.86
US$ 19.99
